A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC

This study aims to evaluate the efficacy and safety of SBRT combined with Puterizumab immunotherapy for non-small cell lung cancer with pulmonary metastases, and to determine the correlation between MRD and treatment efficacy. Through single-cell sequencing and spatial transcriptome information analysis, the underlying mechanisms will be analyzed to provide a basis for improving the new precision treatment methods for tumor immunotherapy resistance.

NCT Number	NCT06434740
Lead Sponsor	Sir Run Run Shaw Hospital
Conditions	Non-Small-Cell Lung Cancer
Enrollment	37 participants
Start Date	2024-06-01
Primary Completion	2026-12-30 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2024-05-30